Optimi Health Corp. - Common Shares (OPTH)

5.8500
+0.2100 (3.72%)
NASDAQ· Last Trade: Jun 2nd, 5:11 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close5.640
Open5.730
Bid5.860
Ask6.080
Day's Range5.600 - 6.200
52 Week Range4.950 - 6.400
Volume284,229
Market Cap-
PE Ratio (TTM)-
EPS (TTM)-
Dividend & YieldN/A (N/A)
1 Month Average Volume443,709

Chart

News & Press Releases

BioMedNewsBreaks — Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Completes GMP Production Run of 5mg Psilocybin Drug Product
This article has been disseminated on behalf of Optimi Health Corp. and may include paid advertising.
Via Investor Brand Network · June 2, 2026
Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in Australia
Optimi’s 5mg psilocybin capsules are prescribed commercially for treatment-resistant depression in Australia, with additional product from the run earmarked for planned clinical trials in the United States and Europe
By OPTIMI HEALTH CORP. · Via GlobeNewswire · June 2, 2026
NetworkNewsBreaks – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Highlights Australia Psychedelic Therapy Expansion Following TGA Framework Update
This article has been disseminated on behalf of Optimi Health Corp. and may include paid advertising.
Via Investor Brand Network · May 29, 2026
Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in Australia
Updated TGA recommendations broaden therapist eligibility, accept a wider range of treatment settings, and reinforce Australia's position as the world's leading commercial market for prescribed psilocybin and MDMA
By OPTIMI HEALTH CORP. · Via GlobeNewswire · May 29, 2026
PsychedelicNewsBreaks – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Featured in Diamond Equity Research Initiation Report Highlighting Commercial Psychedelics Opportunity
This article has been disseminated on behalf of Optimi Health Corp. and may include paid advertising.
Via Investor Brand Network · May 27, 2026
InvestorNewsBreaks – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Prices $15 Million Public Offering in Connection With Nasdaq Uplisting
This article has been disseminated on behalf of Optimi Health Corp. and may include paid advertising.
Via Investor Brand Network · May 21, 2026
Optimi Health Announces Pricing of Oversubscribed US$15 Million Public Offering and Nasdaq Uplisting
(May 20, 2026) - Optimi Health Corp. (NASDAQ:OPTH) (CSE:OPTI) (FSE: 8BN) (the "Company" or "Optimi"), a commercial-stage pharmaceutical company focused on manufacturing and
Via PressReach · May 20, 2026